| Have health trends worsened in Greece as a result of the financial crisis? A quasi-experimental approach S Vandoros, P Hessel, T Leone, M Avendano The European Journal of Public Health 23 (5), 727-731, 2013 | 208 | 2013 |
| Reforms in the Greek pharmaceutical market during the financial crisis S Vandoros, T Stargardt Health policy 109 (1), 1-6, 2013 | 141 | 2013 |
| Excess mortality during the Covid-19 pandemic: Early evidence from England and Wales S Vandoros Social Science & Medicine 258, 113101, 2020 | 128 | 2020 |
| Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs P Kanavos, A Ferrario, S Vandoros, GF Anderson Health affairs 32 (4), 753-761, 2013 | 118 | 2013 |
| Differences in costs of and access to pharmaceutical products in the EU P Kanavos, S Vandoros, R Irwin, E Nicod, M Casson EPRS: European Parliamentary Research Service, 2011 | 118 | 2011 |
| Determinants of branded prescription medicine prices in OECD countries PG Kanavos, S Vandoros Health economics, policy and law 6 (3), 337-367, 2011 | 89 | 2011 |
| The association between economic uncertainty and suicide in the short-run S Vandoros, M Avendano, I Kawachi Social Science & Medicine 220, 403-410, 2019 | 85 | 2019 |
| The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors F Von der Schulenburg, S Vandoros, P Kanavos Health economics review 1, 1-8, 2011 | 74 | 2011 |
| Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium P Kanavos, L Seeley, S Vandoros LSE Health London School of Economics, 2009 | 73 | 2009 |
| The impact of the Great Recession on health-related risk factors, behaviour and outcomes in England M Jofre-Bonet, V Serra-Sastre, S Vandoros Social Science & Medicine 197, 213-225, 2018 | 72 | 2018 |
| The differential impact of the financial crisis on health in Ireland and Greece: a quasi-experimental approach P Hessel, S Vandoros, M Avendano Public health 128 (10), 911-919, 2014 | 54 | 2014 |
| The generics paradox revisited: empirical evidence from regulated markets S Vandoros, P Kanavos Applied Economics 45 (22), 3230-3239, 2013 | 52 | 2013 |
| The impact of bank competition and concentration on industrial growth G Liu, A Mirzaei, S Vandoros Economics Letters 124 (1), 60-63, 2014 | 41 | 2014 |
| Competition in prescription drug markets: is parallel trade the answer? P Kanavos, S Vandoros Managerial and decision economics 31 (5), 325-338, 2010 | 41 | 2010 |
| Household expenditures for medicines and the role of free medicines in the Brazilian public health system AD Bertoldi, AJD Barros, AL Camargo, PC Hallal, S Vandoros, A Wagner, ... American journal of public health 101 (5), 916-921, 2011 | 40 | 2011 |
| Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP P Kanavos, S Vandoros, P Garcia-Gonzalez Globalization and health 5, 1-13, 2009 | 38 | 2009 |
| Raising the bar for market authorisation of new drugs H Naci, J Cylus, S Vandoros, A Sato, K Perampaladas Bmj 345, 2012 | 37 | 2012 |
| Greasy roads: the impact of bad financial news on road traffic accidents S Vandoros, G Kavetsos, P Dolan Risk analysis 34 (3), 556-566, 2014 | 33 | 2014 |
| Introduction and utilization of high priced HCV medicines across Europe; implications for the future W De Bruijn, C Ibanez, P Frisk, H Bak Pedersen, A Alkan, ... Frontiers in pharmacology 7, 197, 2016 | 30 | 2016 |
| Cyprus in crisis: recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment P Petrou, S Vandoros Health Policy 119 (5), 563-568, 2015 | 29 | 2015 |
Panos KanavosAssociate Professor in International Health PolicyVerified email at lse.ac.uk
